189 related articles for article (PubMed ID: 35704674)
1. Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
Qualls D; Kumar A; Epstein-Peterson ZD
Leuk Lymphoma; 2022 Nov; 63(11):2515-2527. PubMed ID: 35704674
[TBL] [Abstract][Full Text] [Related]
2. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
Papin A; Le Gouill S; Chiron D
Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
[TBL] [Abstract][Full Text] [Related]
3. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies.
Burger JA; Ford RJ
Semin Cancer Biol; 2011 Nov; 21(5):308-12. PubMed ID: 21945516
[TBL] [Abstract][Full Text] [Related]
4. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
Arun Kumar S; Gao J; Patel SA
Leuk Res; 2023 Nov; 134():107385. PubMed ID: 37672954
[TBL] [Abstract][Full Text] [Related]
5. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
6. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
7. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
[TBL] [Abstract][Full Text] [Related]
8. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
9. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
Nayak RK; Gerber D; Zhang C; Cohen JB
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):861-865. PubMed ID: 37661513
[TBL] [Abstract][Full Text] [Related]
10. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
13. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in mantle cell lymphoma.
Kumar A
Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
16. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Martin P; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2019 Aug; 60(8):1853-1865. PubMed ID: 30696305
[TBL] [Abstract][Full Text] [Related]
17. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
20. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
Jain N; Mamgain M; Chowdhury SM; Jindal U; Sharma I; Sehgal L; Epperla N
J Hematol Oncol; 2023 Aug; 16(1):99. PubMed ID: 37626420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
